Information Provided By:
Fly News Breaks for June 7, 2018
Jun 7, 2018 | 07:58 EDT
Following the read-through from Proteostasis' (PTI) data for PTI-801 in CF patients on background Orkambi therapy, RBC Capital analyst Brian Abrahams reaffirmed his view that weakness in Vertex (VRTX) into the readout of similar Phase II CF study data from Galapagos (GLPG) is "unfounded" and presents a buying opportunity for Vertex shares. Abrahams has an Outperform rating and $202 price target on Vertex shares.
News For VRTX;PTI;GLPG From the Last 2 Days
There are no results for your query VRTX;PTI;GLPG